viewCannPal Animal Therapeutics Ltd
This follows chairman Geoff Starr’s on-market share purchases last month.
() non-executive director Robert Johnston has purchased 100,000 shares through on-market trades.
The purchase amounted to $11,911.86 and increased Johnston’s total holding in the company to 300,000 shares.
READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market
CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.
The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.
Last month, CannPal received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.
CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.
CannPal hopes to complete recruitment for both studies by mid CY2019.
ASX:CP1
Market: ASX
Market Cap: $13.5 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market
CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...
on 06/24/2018
2 min read
Prev article
2 min read
